Philadelphia chromosome (Ph)-positive leukaemia cells express the chimeric bcr/abl oncoprotein, whose deregulated protein tyrosine kinase (PTK) activity antagonizes the induction of apoptosis by DNA damaging agents. Treatment of Ph-positive K562, TOM 1 and KCL-22 cells with etoposide for 2d induced cytosolic vacuolation, but not nuclear condensation or DNA fragmentation. The bcr/abl kinase-selective inhibitor herbimycin A increased the induction of nuclear apoptosis by etoposide or g-radiation. The concentration of herbimycin required to synergize with etoposide was similar to that required to decrease the level of tyrosine phosphorylated proteins or of the protein tyrosine kinase activity of anti-abl immune complexes in K562 cells. The ability of herbimycin A to sensitize K562, TOM 1 or KCL-22 cells to apoptosis induction correlated with its ability to decrease the cellular content of phosphotyrosyl proteins in these Philadelphia-positive lines. Enhancement of nuclear apoptosis by herbimycin was not attributable to downregulation of the bcl-2 or bcl-X L anti-apoptotic proteins. In contrast, herbimycin protected Philadelphianegative HL60 cells from apoptosis induction by etoposide and did not aect killing of NC37 and CEM cells. The data suggest that the induction of apoptosis is blocked in cells expressing the bcr/abl oncoprotein and that herbimycin A increases induction of programmed cell death following DNA damage. Selective PTK inhibitors may therefore be of value in securing the genetic death of Ph-positive leukaemia cells.
Philadelphia chromosome (Ph)-positive leukaemia cells express the chimeric bcr/abl oncoprotein, whose deregulated protein tyrosine kinase (PTK) activity antagonizes the induction of apoptosis by DNA damaging agents. Treatment of Ph-positive K562, TOM 1 and KCL-22 cells with etoposide for 2d induced cytosolic vacuolation, but not nuclear condensation or DNA fragmentation. The bcr/abl kinase-selective inhibitor herbimycin A increased the induction of nuclear apoptosis by etoposide or g-radiation. The concentration of herbimycin required to synergize with etoposide was similar to that required to decrease the level of tyrosine phosphorylated proteins or of the protein tyrosine kinase activity of anti-abl immune complexes in K562 cells. The ability of herbimycin A to sensitize K562, TOM 1 or KCL-22 cells to apoptosis induction correlated with its ability to decrease the cellular content of phosphotyrosyl proteins in these Philadelphia-positive lines. Enhancement of nuclear apoptosis by herbimycin was not attributable to downregulation of the bcl-2 or bcl-X L anti-apoptotic proteins. In contrast, herbimycin protected Philadelphianegative HL60 cells from apoptosis induction by etoposide and did not aect killing of NC37 and CEM cells. The data suggest that the induction of apoptosis is blocked in cells expressing the bcr/abl oncoprotein andIntroduction Apoptosis (programmed cell death) is a form of physiological cell death whose hallmarks include cell shrinkage, cytoplasmic vacuolation, nuclear condensation and DNA fragmentation (Ra, 1992; Kerr et al., 1994; Jacobson et al., 1994) . Apoptotic cell death is induced by a variety of stimuli, including the withdrawal of cytokines required for cell survival (Williams et al., 1990; Lotem and Sachs, 1992) , ligation of the cell-surface Fas molecule (Cory, 1994) and DNA damage caused by irradiation or treatment with cytotoxic drugs (Williams and Smith, 1993; Fisher, 1994) .
The variable response of malignant cells to the induction of apoptosis by cytotoxic drugs is dependent in part on dierences in expression or biochemical activity of proteins which regulate this process (Fisher, 1994) . The Philadelphia (Ph) translocation is characteristic of chronic myeloid leukaemia (CML) and results in the expression of a chimeric bcr/abl-encoded protein (p210 bcr/abl ) whose protein tyrosine kinase (PTK) activity is enhanced compared with that of the normal abl protein (Sawyers et al., 1991) . Biochemical pathways initiated by the constitutively activated PTK activity of p210 bcr/abl contribute to the protection of hemopoietic cells from the induction of apoptosis induced by cytokine withdrawal (Bedi et al., 1994) , Fas ligation (McGahon et al., 1995) and treatment with cytotoxic drugs (McGahon et al., 1994) or dimethyl sulphoxide (Zhu et al., 1996) . Activation of a temperature-sensitive p210 bcr/abl mutant protects BaF3 cells from apoptosis following irradiation or etoposide treatment (Nishii et al., 1996) , con®rming the antiapoptotic actions of the chimeric protein. A variant Ph chromosome detected in some cases of acute lymphoblastic leukaemia (ALL) encodes a smaller protein (p190 bcr/abl ), with increased transforming properties compared to p210 bcr/abl (Kurzrock et al., 1988) . Herbimycin A (HMA) irreversibly inhibits protein tyrosine kinases including those encoded by the bcr/abl and src genes (Okabe and Uehara, 1993) . Treatment of Philadelphia-positive K562 cells with HMA abolishes the activity of p210 bcr/abl in a subsequent immune complex kinase assay (Okabe et al., 1994a,b) . HMA is selective for non-receptor protein tyrosine kinases and does not inhibit receptor-type kinases (Okabe and Uehara, 1993) . Nanomolar concentrations of HMA preferentially inhibit proliferation of Philadelphiapositive cell lines (Okabe et al., 1994a,b) . By contrast, genistein, a selective antagonist of receptor-type protein tyrosine kinases does not preferentially inhibit proliferation of cells expressing the bcr/abl oncoprotein (Okabe et al., 1994b; Sato et al., 1994) . HMA blocks the killing of mice inoculated with the v-abl-expressing C1 myeloid leukaemia cell line but does not protect from tumours induced by the abl-negative M1 line (Honma et al., 1992) .
The inherent resistance of Ph-positive cells to cytotoxic therapy is a major impediment to the management of CML. Antisense oligonucleotides which downregulate expression of p210 bcr/abl sensitize Ph-positive cell lines to apoptosis induction by DNA damaging agents (McGahon et al., 1994) or Fas ligation (McGahon et al., 1995) in vitro. However, antisense bcr/abl is not eective in all Ph-positive cell lines and some of these reagents induce apoptosis without reducing p210 bcr/abl levels . Furthermore, problems associated with poor cellular uptake of these agents (Clark, 1995) and with their speci®city (O'Brien et al., 1994; Vaerman et al., 1995; suggest that alternative approaches may be of value. We therefore explored the eect of nanomolar levels of HMA on the induction of apoptosis in Ph-positive leukaemia cell lines exposed to the topoisomerase II inhibitor etoposide or to girradiation.
Results

Synergistic induction of apoptosis by HMA and etoposide treatment of Ph-positive K562 cells
The morphology of untreated K562 Ph-positive CML cells is shown in Figure 1a . Treatment with 5 mM etoposide for 2 days did not result in the induction of nuclear condensation, although an increase in the proportion of cells with large vacuoles was seen (Figure 1b ). HMA alone (200 nM) also failed to induce apoptosis (Figure 1c ). By contrast, co-incubation of K562 cells with 5 mM etoposide and 200 nM HMA resulted in a substantial induction of nuclear condensation and fragmentation (Figure 1d ). The induction of vacuolation by etoposide alone ( Figure  2b ) and of chromatin condensation and nuclear fragmentation by co-incubation with etoposide and HMA (Figure 2d and e) was con®rmed by electron microscopy.
The induction of nuclear condensation in K562 cells incubated with increasing concentrations of etoposide in the presence or absence of 200 nM HMA is shown in Figure 3a and b. Although 5 mM etoposide alone induced little nuclear condensation after 1 or 2 days incubation, higher concentrations of the inhibitor induced signi®cant apoptosis. However, the nuclear condensation induced by 5 or 10 mM etoposide in the presence of 200 nM HMA exceeded the apoptosis induction by either drug alone. This synergistic induction of the nuclear features of apoptosis was evident after 1 day of incubation (Figure 3a ) but was more obvious at 2 days (Figure 3b ). In the presence of HMA, the percentage of condensed nuclei detected at 2 days incubation with 20 or 50 mM etoposide was lower than that seen in the presence of 5 or 10 mM inhibitor ( Figure 3b) . A plausible explanation for this observation is that K562 cells undergo apoptosis more rapidly at higher etoposide concentrations. This is consistent with our observation that the rate of cell loss, as determined by counting of trypan blue-excluding cells, was substantially greater at the higher levels of inhibitor (data not shown). Immunoblot analysis of fresh CML cells as well as cell lines established from dierent CML patients shows a consistent pattern of protein bands phosphorylated on tyrosine residues (Naldini et al., 1986; Evans et al., 1987) . Furthermore, phosphotyrosyl proteins are substantially more abundant in Ph-positive cell lines than in lines established from Ph-negative leukaemias (Okabe et al., 1994a) . It is therefore likely that the majority of phosphotyrosyl protein bands detected in the CML lines studied here re¯ect the activity of chimeric bcr/abl kinases. We observed that 200 nM HMA was required to substantially decrease the cellular content of phosphotyrosyl proteins of K562 cells (Figure 4a ), in agreement with previous data (Okabe et al., 1994b) . The induction of nuclear condensation in synergy with 5 mM etoposide also became evident at 200 nM HMA (Figure 3c) , consistent with the interpretation that the ability of HMA to enhance cell killing by etoposide was attributable to inhibition of PTK activity of p210 bcr/abl by the drug. The decrease in phosphotyrosyl protein content following HMA treatment was not attributable to the reduced expression of p210 bcr/abl ( Figure 4b , lanes 1 ± 4). Allowing for the decreased intensity of the actin bands in lanes 5 and 6, it was evident that 5 mM etoposide added on its own or in the presence of 200 nM HMA also failed to decrease expression of the chimeric protein.
We further con®rmed the dose response of inhibition of p210 bcr/abl by studying the in vitro phosphorylation of Incubation with 100 nM HMA resulted in 45% inhibition, whereas 200 nM of the drug caused a 70% loss of activity (Table 1) . It is plausible that PTK activity needs to be decreased below a de®ned threshold in order that the block on apoptosis induction be abrogated. The dose response characteristics reported here are in excellent agreement with data obtained by autophosphorylation of anti-abl immunoprecipitates (Okabe et al., 1994a,b) . As expected, etoposide treatment failed to inhibit PTK activity in the immune complex assay (Table 1) .
Ten micromolar genistein, a PTK inhibitor which is not selective for p210 bcr/abl (Okabe and Uehara, 1993) , failed to synergize with etoposide in inducing apoptosis of K562 cells (data not shown). This concentration of genistein, which is sucient to block the ability of stem cell factor to protect natural killer cells from spontaneous apoptosis (Carson et al., 1994) , failed to decrease the cellular content of phosphotyrosyl proteins (Figure 4c ), again suggesting that the ability to speci®cally inhibit p210 bcr/abl is a requirement for the enhancement of apoptosis by PTK inhibitors.
Synergistic killing of K562 cells by etoposide and HMA was also evident when viability was assessed by the MTT assay ( Table 2 ). Detection of nuclear DNA fragmentation by the TUNEL assay additionally con®rmed the enhancement of apoptosis induction by this drug combination (Figure 5a ). However, the percentage of TUNEL-positive cells generated in the presence of the drug combination was approximately half the percentage of cells showing nuclear condensation under the same conditions. Others have also observed that DNA degradation is not always detected in cells undergoing apoptosis as de®ned by morphological criteria (Tomei et al., 1993; Ucker et al., 1992) .
HMA does not synergize with etoposide in inducing apoptosis in Ph-negative cell lines
We then investigated the action of HMA on the induction of apoptosis in Ph-negative HL60 cells treated with etoposide. Etoposide alone induced substantial nuclear condensation at concentrations between 1 and 10 mM (Figure 3d ), in agreement with previous observations (Bertrand et al., 1993) . In complete contrast to our observations on K562 cells, HMA dramatically decreased the induction of apoptotic nuclear changes in HL60 cells (Figure 5a ). This protective eect was also evident when loss of cell viability was evaluated using the MTT assay ( Table 2 ). The ability of HMA to protect HL60 cells from etoposide-induced nuclear DNA fragmentation was also strikingly demonstrated using the TUNEL assay (Figure 5b ). Two other Ph-negative leukaemia cell lines (CEM and NC37) were sensitive to etoposide alone (1 to 5 mM). HMA (200 nM) did not aect either the induction of nuclear condensation or the loss of HMA does not decrease expression of bcl-2 or bcl-X L anti-apoptotic proteins
The susceptibility of cells to the induction of apoptosis is determined in part by the ratio between antiapoptotic proteins, including bcl-2 and bcl-X L and promoters of cells death including bax (Yang and Korsmeyer, 1996) . Because ectopic expression of bcr/ abl transgenes results in elevated expression of bcl-2 protein (Sanchez-Garcia and Grutz, 1995; Zhu et al., 1996) , it was plausible that the ability of HMA to enhance etoposide-and g-radiation-induced apoptosis may be attributable to downregulation of expression of anti-apoptotic genes consequent to the inhibition of the PTK activity of p210 bcr/abl . We therefore used a competitive reverse transcriptase polymerase chain reaction (RT ± PCR) technique to determine the actions of etoposide and HMA on the expression of mRNAs encoding three bcl-2 family genes. The expression of actin mRNA was essentially unchanged following 24 h incubation of K562 cells with either drug on its own or in combination (Figure 7) . By contrast, the expression of both bcl-2 and bcl-X L mRNA were markedly decreased following incubation with etoposide, HMA or etoposide plus HMA. Expression of bax mRNA was also downregulated by these treatments (Figure 7) . K562 cells express relatively low levels of bcl-2 protein compared to other leukemic cell lines (Steube et al., 1995) . However, expression of bcl-X L (FAR, unpublished data) and of bax (Steube et al., 1995) are comparable to levels detected in other lines. In contrast to the dramatic downregulation at the mRNA level, Western blot analysis of proteins extracted from control K562 cells and from cells treated with drugs for 24 or 48 h showed that expression of the bcl-2, bcl-X L or bax proteins was essentially unchanged (relative to the expression of actin) following incubation with Primer sequences: primer R: ACA ACA TCG CCC TGT GGA TGA C; Primer D: ATA GCT GAT TCG ACG TTT TGC C; Bax 1: GGA ATT CTG ACG GCA ACT TCA ACT GGG; Bax 2: GGA ATT CTT CCA GAT GGT GAG CGA GG; Actin 1: TGC TAT CCA GGC TGT GCT AT; Actin 2: GAT GGA GTT GAA GGT AGT TT. Actin primer sequences were provided by Dr L Foroni. The bcl-2 and bax primer sequences were obtained by analysis of published sequence data using MacVector software (Symantec, USA). Nucleotides in bold were added to provide restriction sites for cloning either etoposide or HMA alone or with a combination of these drugs which synergistically induced nuclear apoptosis (Figure 8 ). The maintenance of high levels of bcl-2 family proteins despite the dramatic reduction in the levels of their transcripts may re¯ect the relative stability of the proteins compared to their mRNAs. For example, the bcl-2 transcript has a half-life of a few hours while that of the bcl-2 protein is in excess of one day (Blagosklonny et al., 1996; Reed, 1996) . Therefore, although HMA treatment decreases the levels of bcl-2 family transcripts, it is unlikely that the ability of the drug to enhance apoptosis is attributable to this mechanism, since we were unable to detect decreased expression at the protein level. Immunoblot analysis suggested a plausible molecular basis for the dierent susceptibilities of these CML cell lines to sensitization by HMA. KCL-22 cells contained substantially higher levels of phosphotyrosyl proteins than did Tom1 or K562 cells (Figure 4d) . Furthermore, the ability of 200 nM HMA to decrease the cellular content of these proteins was more pronounced in the TOM 1 cells than in KCL-22 cells, correlating with the ability of the drug to enhance apoptosis.
Anti-abl immune complex assays (Table 1) showed that neither the basal PTK activities of these lines nor the ability of HMA to inhibit this activity accounted completely for the large dierences in the intensity of phosphotyrosyl bands of KCL-22 and Tom 1 cells or the relative decrease in these bands following HMA treatment (Figure 4d ).
Discussion
Here we have shown that three Ph-positive leukemic cell lines were more resistant to the induction of nuclear condensation and DNA fragmentation following etoposide treatment compared to three Ph-negative lines. Incubation of the Ph-positive lines with nanomolar levels of HMA enhanced the induction of nuclear apoptotic features by etoposide and also by girradiation. A substantial synergy between HMA and etoposide or g-irradiation was seen in the K562 and TOM 1 lines whereas a less pronounced enhancement of apoptosis was seen in the KCL 22 line.
Prominent cytoplasmic vacuolation was nevertheless evident in K562 cells treated with concentrations of etoposide which failed to induce nuclear apoptotic changes. Vacuolation is a cytoplasmic feature of apoptosis in some cell types (Jacobson et al., 1994) . Therefore, the data here suggest that expression of p210 bcr/abl prevents induction of nuclear apoptotic changes without aecting the cytoplasmic changes following etoposide treatment and that simultaneous incubation with the PTK inhibitor HMA relieves the block in induction of nuclear condensation and DNA fragmentation. The independent regulation of cytoplasmic and nuclear features of apoptosis is in accord with the observation that cytoplasts were capable of undergoing programmed cell death in the absence of a nucleus (Jacobson et al., 1994) .
Several lines of evidence suggest that the ability of HMA to enhance nuclear apoptotic changes following induction of DNA damage in K562 cells is attributable to inhibition of the PTK activity of p210 bcr/abl . First, the Figure 9 Induction of apoptosis of Tom 1 (a,c) or KCL-22 (b,d) cells. Condensed nuclei were estimated in (a) and (b). In (c) and (d), apoptosis was assessed by TUNEL assay concentration of HMA required to synergize with etoposide or g-irradiation is similar to that required to substantially reduce the cellular content of proteins phosphorylated on tyrosine residues in K562 cells. The majority of these phosphorylation events are attributable to the PTK activity of the chimeric bcr/abl protein (Naldini et al., 1986; Evans et al., 1987; Okabe et al., 1994b) .
Second, the ability of HMA to enhance apoptosis induction in three dierent CML cell lines correlated inversely with the basal levels of phosphotyrosyl proteins in these lines and was directly related to the ability of HMA to decrease their phosphorylation.
Third, when K562 or Tom 1 cells were incubated with HMA, the concentration of the drug required to inhibit PTK activity in a subsequent immune complex kinase assay correlated well with that required to sensitize these lines to apoptosis induction. However PTK activity was also inhibited by HMA treatment of KCL-22 cells, which were relatively more resistant to apoptosis induction. It is therefore plausible that the high levels of phosphotyrosyl proteins of KCL-22 cells and their persistence following HMA treatment may be attributable to other factors, which may include a relatively reduced level of protein tyrosine phosphatases in this line.
Fourth, genistein, a PTK inhibitor which is not selective for p210 bcr/abl (Okabe and Uehara, 1993) did not decrease the level of phosphotyrosyl proteins in K562 cells and also failed to enhance the ability of etoposide to induce nuclear condensation. Finally, the action of HMA in three Ph-negative leukaemia cell lines was strikingly dierent to its action in Ph-positive lines. NC37 and CEM cells were susceptible to etoposide-induced apoptosis which was unaected by HMA. In HL60 cells, HMA dramatically inhibited the induction of apoptosis by etoposide. Apoptosis induction in U937 cells was also abrogated by HMA (Ginestier-Verne et al., 1996) . PTKs have been implicated in the triggering of apoptosis in some cellular contexts (Carson et al., 1994; Bergamaschi et al., 1993; Uckun et al., 1992; Uckun et al., 1996) while promoting survival in others (Bedi et al., 1994; McGahon et al., 1994; Zhu et al., 1996) . It is therefore plausible that an HMA-sensitive PTK is part of the signalling pathway which induces apoptosis in HL60 and U937 cells following etoposide treatment.
Transformation of the BaF3 (Sanchez-Garcia and Grutz, 1995) or 32Dc13 (Zhu et al., 1996) murine hemopoietic cell line by expression of the bcr/abl gene results in increased expression of bcl-2 protein and in protection from apoptotic stimuli. We therefore asked whether concentrations of HMA which enhanced the induction of nuclear apoptosis in K562 cells by etoposide also resulted in downregulation of bcl-2 expression. Although HMA treatment caused a marked decrease in the levels of bcl-2 as well as of bcl-X L and bax mRNA 24 h after drug addition, the proteins encoded by these genes continued to be expressed even at 48 h of treatment. Therefore, the ability of HMA to accelerate the induction of nuclear apoptosis in etoposide-treated K562 cells is unlikely to be attributable to changes in expression of these key apoptosis-regulating proteins. Nishii et al. (1996) also failed to observe changes in expression of bcl-2, bcl-X or bax proteins following activation of a temperaturesensitive mutant of p210 bcr/abl expressed in BaF3 cells, although this manipulation resulted in extensive protection from apoptosis following genotoxic damage. A growing family of other bcl-2-related proteins have recently been implicated in the control of programmed cell death (Yang and Korsmeyer, 1996) . It is therefore possible that the action of HMA described here may be attributable to changes in the absolute levels or state of post-translational modification (Gajewski and Thompson, 1996) of proteins other than bcl-2, bcl-X L or bax.
In conclusion, we have shown that nanomolar concentrations of the PTK inhibitor HMA synergize with etoposide or with g-irradiation in inducing the nuclear features of apoptosis in three Philadelphia chromosome-positive leukaemia cell lines. While speci®c antisense oligonucleotides enhance apoptosis induction in bcr/abl-positive cells in vitro (Bedi et al., 1994; McGahon et al., 1994) there are substantial problems associated with the delivery (Clark et al., 1995) and speci®city (O'Brien et al., 1994; Vaerman et al., 1995; of these agents. Therefore, there is substantial interest in the possible use of speci®c protein tyrosine kinase inhibitors in the treatment of leukaemia (Okabe et al., 1992 (Okabe et al., , 1993 (Okabe et al., , 1994 Meydan et al., 1996; Druker et al., 1996) . The novel antagonist CGP 57148 inhibits the protein tyrosine kinase activity of p21 bcr/abl with an IC 50 of 25 nM and is highly selective for abl-encoded enzymes (Druker et al., 1996) . When administered alone, CGP 57148 inhibits the establishment of tumours in syngeneic mice injected with bcr/ablpositive 32Dc13 cells. It is plausible that potent and selective antagonists of this type may display antitumour activity against established bcr/abl-positive tumours when administered in conjunction with conventional cytotoxic treatment.
Materials and methods
Cell culture, drug treatment and irradiation K562 and HL60 cells were obtained from the European Collection of Animal Cell Cultures, Porton Down, Wiltshire, UK. TOM-1 and KCL-22 cells were a gift from Dr Junia Melo. NC37 and CEM cells were obtained from Dr K Ganeshaguru. All cell lines were routinely cultured in RPMI 1640 medium supplemented with 10% fetal calf serum and antibiotics (Life Technologies, Paisley, Scotland). Etoposide and HMA were obtained from Calbiochem (Nottingham, UK). Genistein was from Sigma (Poole, UK). Stock solutions of drugs were prepared in dimethyl sulphoxide. Concentrations of dimethyl sulphoxide added to cultures did not exceed 0.1%. For drug treatment, cultures were initiated at 3610 5 cells. ml 71 . Cells were irradiated by exposure to a 137 Cs source using a Gammacell irradiator (Nordion, Canada).
Morphological assessment of apoptotic cell killing
Cytospin preparations of cells were stained with MayGrunwald-Giemsa. Apoptotic cell death was quanti®ed by estimating the proportion of cells with condensed chromatin or fragmented nuclei. Slides were examined in random order and at least 400 cells were counted for each estimation. Each experiment was repeated at least three times and evaluated by three independent observers. The morphology of drug-treated cells was additionally con®rmed by electron microscopic observation of uranyl acetate-stained sections.
Terminal deoxynucleotidyl transferase-mediated dUTP end labelling (TUNEL) assay TUNEL assays were carried out using the Apoptosis Detection System (Promega, Southampton, UK). Brie¯y, cytospin preparations of cells were incubated with terminal deoxynucleotidyl transferase and¯uorescein-12-dUTP. Cell nuclei containing DNA strand breaks were labelled and were quantitated by¯uorescence microscopy.
MTT assay
The ability of viable cells to reduce 3-4,5-dimethylthiazol-2,5-diphenyl tetrazolium bromide (MTT; Sigma, Poole, UK) was determined essentially as described (Twentyman et al., 1989) . The absorbance of the purple formazan generated was quantitated using a plate reader.
RNA extraction and reverse transcription
RNA was extracted using the guanidinium isothiocyanateacid phenol procedure (Chomzynski and Sacchi, 1987) . cDNA was prepared using Moloney murine leukaemia virus reverse transcriptase (Life Technologies, Paisley, Scotland) and random hexamer primers (Boehringer, East Sussex, UK). A reverse transcriptase blank containing 1 mg of yeast tRNA was included with each set of RNA preparations analysed.
Competitive RT ± PCR
Primers for the RT ± PCR analysis of the bcl-2, bax and actin genes are summarized in Table 2 . Bcl-x primers were as described (Boise et al., 1993) .
Mimic templates for competitive RT ± PCR of bcl-2 cDNA were constructed essentially as described (Siebert and Larrick, 1993) , and consisted of luciferase gene sequences (Promega Technical Manual, 1993) ¯anked by the R and D primers ( Table 2) . Use of the R and D primers to co-amplify the mimic templates in the presence of cDNA preparations resulted in the generation of a 549 nt product from the mimic and a 409 nt product from bcl-2 cDNA. Mimic templates for competitive RT ± PCR analysis of actin, bcl-X and bax cDNAs were constructed in a similar manner.
Competitive RT ± PCR analysis (Siebert and Larrick, 1993) of cDNA preparations were carried out in 25 ml reactions using Taq DNA polymerase (Life Technologies, Scotland). PCR products were fractionated by agarose gel electrophoresis, transferred to Hybond N membranes (Amersham International, Little Chalfont, UK) and detected by hybridization to sequence-speci®c riboprobes generated by in vitro transcription of sequences cloned into the bluescript vector (Stratagene, UK). Filters were then stripped and reexposed to a luciferase speci®c probe for detection of the band generated by ampli®cation of the mimic template.
Western blot analysis
Bcl-2, bcl-X, bax, actin and proteins phosphorylated on tyrosine residues were detected by Western blotting using antibodies from Santa Cruz Biotechnology, Santa Cruz, CA. p210 bcr/abl and p145 abl were detected using the Ab-3 anti-abl antibody (Calbiochem, Nottingham, UK). Immunoreactive bands were displayed using the ECL light detection system (Amersham International, Little Chalfont, UK).
Immune complex kinase assays
Anti-abl reactive proteins were immunoprecipitated essentially as described by Konopka and Witte (1985) , using a modi®ed protocol kindly provided by Drs L Wiedemann and J Kabarowski. Washed immunoprecipitates were incubated for 30 min at 378C in 100 ml reactions containing 50 mm Tris-HCl (pH 7.5), 10 mM MgCl2, 5 mM MnCl2, 50 mM sodium orthovanadate, 0.05% nonidet P40, 0.2 mM [g-32 P] ATP (1 mCi nmol 71 ), and 1 mg ml 71 of poly(glutamate.tyrosine) (Sigma, Poole, UK). Incorporation of radiolabel into the synthetic polymer was determined following removal of the immune complex by centrifugation and precipitation of the resulting supernatant with 0.5 M perchloric acid. Blank incubations omitting the polymer were also performed. Preliminary experiments (not shown) established that 480% of the PTK activity present in crude lysates was precipitated by the protocol used here.
